{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-069414","form_type":"8-K","ticker":"AKTX","cik":"0001541157","company_name":"Akari Therapeutics Plc","filed_at":"2024-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.906307+00:00","generated_at":"2026-06-01T06:15:31.283121+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Akari Therapeutics formalizes interim CEO compensation: $50k/month in equity, no cash/benefits/severance","bullets":["Samir R. Patel appointed Interim President & CEO effective May 1; agreement signed May 31.","Compensation entirely equity-based: $50,000/month in fully vested ordinary shares valued at monthly closing price.","No annual bonus, employee benefits, or severance entitlements; at-will independent contractor role.","Company may terminate agreement immediately for any reason."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-069414","json":"https://secwatch.observer/filing/0000950170-24-069414.json","markdown":"https://secwatch.observer/filing/0000950170-24-069414.md","text":"https://secwatch.observer/filing/0000950170-24-069414.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024069414/0000950170-24-069414-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024069414/aktx-20240531.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:15:31.283121+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"34ba5e8e80","claim":"Samir R. Patel was appointed as Interim President and Chief Executive Officer at Akari Therapeutics Plc.","evidence_excerpt":"As previously disclosed, on April 25, 2024, the board of directors (the “Board”) of Akari Therapeutics, Plc (the “Company”) appointed Samir R. Patel, M.D., a member of the Board, as Interim President and Chief Executive Officer, effective May 1, 2024, to serve in such capacities until such time as determined by the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024069414/0000950170-24-069414-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}